Who owns ARTIVA BIOTHERAPEUTICS INC?
- Ticker: ARTV
- CUSIP Number: 04317a107
Tip: Access positions for across all investors
Analyze quarterly positions in Artiva Biotherapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Artiva Biotherapeutics stock
Who bought or sold ARTIVA BIOTHERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| RA Capital Management | 9.9M | $64M | 0% | Mar 2026 |
|
| 5AM Venture Management | 2.4M | $15M | 0% | Mar 2026 |
|
| VR Adviser | 1.6M | $10M | 0% | Mar 2026 |
|
| venBio Partners | 531k | $3.4M | -18% | Mar 2026 |
|
| Franklin Resources | 520k | $3.4M | 0% | Mar 2026 |
|
| Revelation Capital Management | 299k | $1.3M | 100% | Dec 2025 |
|
| Vanguard Group | 246k | $1.1M | 55% | Dec 2025 |
|
| BlackRock | 213k | $1.4M | 0% | Mar 2026 |
|
| Vanguard Capital Management | 208k | $1.3M | 100% | Mar 2026 |
|
| Wellington Management Company | 194k | $833k | 0% | Dec 2025 |
|
| Propel Bio Management | 146k | $950k | 100% | Mar 2026 |
|
| Millennium Management | 123k | $794k | -43% | Mar 2026 |
|
| Renaissance Technologies | 116k | $499k | 47% | Dec 2025 |
|
| Two Sigma Investments | 115k | $741k | -21% | Mar 2026 |
|
| Geode Capital Management | 102k | $656k | 1% | Mar 2026 |
|
| Alyeska Investment Group | 100k | $644k | 0% | Mar 2026 |
|
| Marshall Wace | 80k | $341k | 100% | Dec 2025 |
|
| Jane Street | 40k | $254k | -3% | Mar 2026 |
|
| State Street Corporation | 36k | $154k | -40% | Dec 2025 |
|
| Bridgeway Capital Management | 35k | $150k | 0% | Dec 2025 |
|
| Vanguard Fiduciary Trust | 33k | $211k | 100% | Mar 2026 |
|
| PanAgora Asset Management | 31k | $198k | 100% | Mar 2026 |
|
| Simplify Asset Management | 23k | $150k | 100% | Mar 2026 |
|
| Sanctuary Advisors | 22k | $139k | 100% | Mar 2026 |
|
| Bailard | 21k | $133k | 100% | Mar 2026 |
|
| Dimensional Fund Advisors | 20k | $131k | 100% | Mar 2026 |
|
| Morgan Stanley | 16k | $106k | -40% | Mar 2026 |
|
| Citadel Advisors | 16k | $102k | 100% | Mar 2026 |
|
| Goldman Sachs Group | 12k | $74k | -5% | Mar 2026 |
|
| OMERS Administration Corporation | 11k | $73k | -46% | Mar 2026 |
|
| Springbok Capital Management | 11k | $46k | -25% | Dec 2025 |
|
| Russell Investments | 5.5k | $35k | 0% | Mar 2026 |
|
| FMR | 3.6k | $15k | -28% | Dec 2025 |
|
| UBS Group | 1.5k | $9.8k | -96% | Mar 2026 |
|
| Wells Fargo & Company | 1.5k | $9.7k | 0% | Mar 2026 |
|
| Tower Research Capital | 1.1k | $4.7k | -89% | Dec 2025 |
|
| Bnp Paribas Arbitrage, Snc | 542.00 | $3.5k | 0% | Mar 2026 |
|
| Mark Sheptoff Financial Planning | 400.00 | $4.2k | 0% | Mar 2026 |
|
| Royal Bank of Canada | 188.00 | $999.990800 | -78% | Mar 2026 |
|
| Advisor Group Holdings | 32.00 | $136.998400 | 100% | Dec 2025 |
|
Who sold out of Artiva Biotherapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| XTX Topco | Sep 2025 | 48k | $138k |
| Scientech Research | Dec 2025 | 28k | $119k |
| Qube Research & Technologies | Sep 2025 | 26k | $73k |
| Barclays | Sep 2025 | 13k | $36k |
| Jpmorgan Chase & Co | Sep 2025 | 4.0k | $12k |